Article Text

Download PDFPDF
Oestrogen receptor β immunohistochemistry: time to get it right?
  1. V Speirs1,
  2. C A Green1,
  3. A M Shaaban2
  1. 1Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
  2. 2St James’s Institute of Oncology, St James’s University Hospital, Leeds, UK
  1. Dr V Speirs, Leeds Institute of Molecular Medicine, Wellcome Trust Brenner Building, St James’s University Hospital, Leeds LS9 7TF, UK; v.speirs{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the paper by Borgquist et al, published recently in this journal.1 In their article, the authors aimed to investigate the impact of oestrogen receptor β (ERβ) expression on breast cancer outcome using a cohort of 512 tumours represented in tissue microarray (TMA). Since the discovery of ERβ over a decade ago, this has been the goal of many research groups. However, progress in this area has been impeded by the lack of a consensus in terms of choice of primary antibody and cut-off value used to determine ERβ positivity.2 3 Additionally, we know that ERβ exists as five isoforms (ERβ1–5), each formed by alternative splicing of the last coding exon,4 5 which …

View Full Text


  • Competing interests: None.

Linked Articles

  • Letters
    S Borgquist C Holm M Stendahl L Anagnostaki G Landberg K Jirström